Skip to Main Content
Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2017, Issue 1
December 8 2017
Issue Cover
In this Issue

Table of Contents

Ham-Wasserman Lecture

AL amyloidosis: from molecular mechanisms to targeted therapies
Giampaolo Merlini
View Articletitled, AL amyloidosis: from molecular mechanisms to targeted therapies

Acute Lymphocytic Leukemia: New Approaches in Management

Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation
Monika Brüggemann,Michaela Kotrova
View Articletitled, Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation
Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation
Farhad Ravandi
View Articletitled, Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation
Progress in adult ALL: incorporation of new agents to frontline treatment
Jessica Leonard,Wendy Stock
View Articletitled, Progress in adult ALL: incorporation of new agents to frontline treatment

Acute Myeloid Leukemia: How Can We Improve Upon Standard Therapy?

Classification and risk assessment in AML: integrating cytogenetics and molecular profiling
Matahi Moarii,Elli Papaemmanuil
View Articletitled, Classification and risk assessment in AML: integrating cytogenetics and molecular profiling
How and when to decide between epigenetic therapy and chemotherapy in patients with AML
Hervé Dombret,Raphael Itzykson
View Articletitled, How and when to decide between epigenetic therapy and chemotherapy in patients with AML
The role of targeted therapy in the management of patients with AML
Alexander E. Perl
View Articletitled, The role of targeted therapy in the management of patients with AML

Bone Marrow Failure: Acquired

Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age
Jaroslaw P. Maciejewski,Suresh K. Balasubramanian
View Articletitled, Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age
Aging, hematopoiesis, and the myelodysplastic syndromes
Stephen S. Chung,Christopher Y. Park
View Articletitled, Aging, hematopoiesis, and the myelodysplastic syndromes
Acquired ribosomopathies in leukemia and solid tumors
Adrianna Vlachos
View Articletitled, Acquired ribosomopathies in leukemia and solid tumors

Bone Marrow Failure: Inherited

Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes
Allison H. West,Jane E. Churpek
View Articletitled, Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes
Inherited bone marrow failure syndromes: considerations pre- and posttransplant
Blanche P. Alter
View Articletitled, Inherited bone marrow failure syndromes: considerations pre- and posttransplant
Treatment of inherited bone marrow failure syndromes beyond transplantation
Rodrigo T. Calado,Diego V. Clé
View Articletitled, Treatment of inherited bone marrow failure syndromes beyond transplantation

Chronic Myeloid Leukemia: Where Are We in the Current TKI Era?

Treatment-free remission in CML: who, how, and why?
Francois-Xavier Mahon
View Articletitled, Treatment-free remission in CML: who, how, and why?
Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy
Mary C. Barber,Michael J. Mauro,Javid Moslehi
View Articletitled, Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy
Novel approaches to therapy in CML
Ravi Bhatia
View Articletitled, Novel approaches to therapy in CML

Common Clinical Questions in Cancer-Associated Venous Thromboembolism

Incidental venous thromboembolism: is anticoagulation indicated?
Marcello Di Nisio,Marc Carrier
View Articletitled, Incidental venous thromboembolism: is anticoagulation indicated?
When can we stop anticoagulation in patients with cancer-associated thrombosis?
Agnes Y. Y. Lee
View Articletitled, When can we stop anticoagulation in patients with cancer-associated thrombosis?
Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?
Ingrid Pabinger,Julia Riedl
View Articletitled, Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?

Common Hematologic Consults in Pregnancy

Thrombocytopenia in pregnancy
Douglas B. Cines,Lisa D. Levine
View Articletitled, Thrombocytopenia in pregnancy
Iron deficiency in gynecology and obstetrics: clinical implications and management
Christian Breymann,Michael Auerbach
View Articletitled, Iron deficiency in gynecology and obstetrics: clinical implications and management
Preventing venous thromboembolism during pregnancy and postpartum: crossing the threshold
Leslie Skeith
View Articletitled, Preventing venous thromboembolism during pregnancy and postpartum: crossing the threshold
Evidence-Based Minireview
Diagnosis and management of postpartum ovarian vein thrombosis
Bethany T. Samuelson Bannow,Leslie Skeith
View Articletitled, Diagnosis and management of postpartum ovarian vein thrombosis

Congenital and Acquired Neutropenia

New monogenic disorders identify more pathways to neutropenia: from the clinic to next-generation sequencing
Seth J. Corey,Usua Oyarbide
View Articletitled, New monogenic disorders identify more pathways to neutropenia: from the clinic to next-generation sequencing
Chronic neutropenia in LGL leukemia and rheumatoid arthritis
Tal Gazitt,Thomas P. Loughran, Jr.
View Articletitled, Chronic neutropenia in LGL leukemia and rheumatoid arthritis
Non–chemotherapy drug–induced neutropenia: key points to manage the challenges
Brian R. Curtis
View Articletitled, Non–chemotherapy drug–induced neutropenia: key points to manage the challenges

Controversies in Myeloma

Shall we treat smoldering multiple myeloma in the near future?
Ola Landgren
View Articletitled, Shall we treat smoldering multiple myeloma in the near future?
Is molecular remission the goal of multiple myeloma therapy?
Faith E. Davies
View Articletitled, Is molecular remission the goal of multiple myeloma therapy?
Fixed duration vs continuous therapy in multiple myeloma
Heinz Ludwig,Niklas Zojer
View Articletitled, Fixed duration vs continuous therapy in multiple myeloma

Controversies in Venous Thromboembolism: To Treat or Not to Treat

Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis
Jan Beyer-Westendorf
View Articletitled, Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis
Should we diagnose and treat distal deep vein thrombosis?
Helia Robert-Ebadi,Marc Righini
View Articletitled, Should we diagnose and treat distal deep vein thrombosis?
Symptomatic subsegmental pulmonary embolism: to treat or not to treat?
Marc Carrier,Fredrikus A. Klok
View Articletitled, Symptomatic subsegmental pulmonary embolism: to treat or not to treat?

Dilemmas in Pediatric Hematologic Malignancy

Pediatric leukemia susceptibility disorders: manifestations and management
Lisa J. McReynolds,Sharon A. Savage
View Articletitled, Pediatric leukemia susceptibility disorders: manifestations and management
Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment)
Rachael Hough,Ajay Vora
View Articletitled, Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment)
Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia
Lewis B. Silverman
View Articletitled, Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia

Emerging Issues in Clinical Care in Thalassemia

Iron overload in thalassemia: different organs at different rates
Ali T. Taher,Antoine N. Saliba
View Articletitled, Iron overload in thalassemia: different organs at different rates
Impact of bone disease and pain in thalassemia
Antonio Piga
View Articletitled, Impact of bone disease and pain in thalassemia
New therapeutic targets in transfusion-dependent and -independent thalassemia
M. Domenica Cappellini,Irene Motta
View Articletitled, New therapeutic targets in transfusion-dependent and -independent thalassemia

Evolving Strategies in Aggressive B-Cell Lymphoma

Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
Andrew Davies
View Articletitled, Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies
Kieron Dunleavy
View Articletitled, Primary mediastinal B-cell lymphoma: biology and evolving therapeutic strategies
Optimizing therapy for mantle cell lymphoma
Peter Martin
View Articletitled, Optimizing therapy for mantle cell lymphoma
Evidence-Based Minireview
Current treatment of double hit and double expressor lymphoma
Patrick M. Reagan,Andrew Davies
View Articletitled, Current treatment of double hit and double expressor lymphoma

Hodgkin Lymphoma: New Insights and New Approaches

Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
W. Robert Liu,Margaret A. Shipp
View Articletitled, Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution
Nancy L. Bartlett
View Articletitled, Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management
Dennis A. Eichenauer,Andreas Engert
View Articletitled, Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management

Individualizing Therapy in Chronic Lymphocytic Leukemia

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment
Gianluca Gaidano,Davide Rossi
View Articletitled, The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment
Optimizing frontline therapy of CLL based on clinical and biological factors
Kirsten Fischer,Michael Hallek
View Articletitled, Optimizing frontline therapy of CLL based on clinical and biological factors
How should we sequence and combine novel therapies in CLL?
Matthew S. Davids
View Articletitled, How should we sequence and combine novel therapies in CLL?
Evidence-Based Minireview
Safety profiles of novel agent therapies in CLL
Inhye E. Ahn,Matthew S. Davids
View Articletitled, Safety profiles of novel agent therapies in CLL

Indolent Lymphoma: How Understanding Disease Biology Is Influencing Clinical Decision-Making

Follicular lymphoma: are we ready for a risk-adapted approach?
Brad S. Kahl
View Articletitled, Follicular lymphoma: are we ready for a risk-adapted approach?
Toward personalized treatment in Waldenström macroglobulinemia
Jorge J. Castillo,Steven P. Treon
View Articletitled, Toward personalized treatment in Waldenström macroglobulinemia
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma
Catherine Thieblemont
View Articletitled, Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma

It All Starts Here: Disorders of Primary Hemostasis

Advances in the diagnosis and treatment of Von Willebrand disease
Ruchika Sharma,Veronica H. Flood
View Articletitled, Advances in the diagnosis and treatment of Von Willebrand disease
Hereditary thrombocytopenias: a growing list of disorders
Patrizia Noris,Alessandro Pecci
View Articletitled, Hereditary thrombocytopenias: a growing list of disorders
Management of newly diagnosed immune thrombocytopenia: can we change outcomes?
Cindy E. Neunert
View Articletitled, Management of newly diagnosed immune thrombocytopenia: can we change outcomes?

Lessons Learned From Quality Improvement Initiatives in Sickle Cell Disease

Five lessons learned about long-term pain management in adults with sickle cell disease
Joshua J. Field
View Articletitled, Five lessons learned about long-term pain management in adults with sickle cell disease
Improving Emergency Department-Based Care of Sickle Cell Pain
Jeffrey A. Glassberg
View Articletitled, Improving Emergency Department-Based Care of Sickle Cell Pain
Rigorous and practical quality indicators in sickle cell disease care
Suzette O. Oyeku,Elissa Z. Faro
View Articletitled, Rigorous and practical quality indicators in sickle cell disease care

Management of Sickle Cell Disease: Present and Future

Cardiovascular complications in patients with sickle cell disease
Mark T. Gladwin
View Articletitled, Cardiovascular complications in patients with sickle cell disease
Chronic organ failure in adult sickle cell disease
Elliott Vichinsky
View Articletitled, Chronic organ failure in adult sickle cell disease
Evolving treatment paradigms in sickle cell disease
Ramasamy Jagadeeswaran,Angela Rivers
View Articletitled, Evolving treatment paradigms in sickle cell disease
Evidence-Based Minireview
What is the role of screening for pulmonary hypertension in adults and children with sickle cell disease?
Shaina M. Willen,Mark T. Gladwin
View Articletitled, What is the role of screening for pulmonary hypertension in adults and children with sickle cell disease?

Myelodysplastic Syndromes: Understanding the Current Treatment Landscape

Uncoding the genetic heterogeneity of myelodysplastic syndrome
R. Coleman Lindsley
View Articletitled, Uncoding the genetic heterogeneity of myelodysplastic syndrome
Current treatment algorithm for the management of lower-risk MDS
Aristoteles Giagounidis
View Articletitled, Current treatment algorithm for the management of lower-risk MDS
Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents
Olatoyosi Odenike
View Articletitled, Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents

Myeloproliferative Neoplasms: New Insights in the Current Treatment Paradigm

Myeloproliferative neoplasms: from origins to outcomes
Jyoti Nangalia,Anthony R. Green
View Articletitled, Myeloproliferative neoplasms: from origins to outcomes
What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?
Alessandro M. Vannucchi,Paola Guglielmelli
View Articletitled, What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?
Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond
Claire N. Harrison,Donal P. McLornan
View Articletitled, Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond

Novel Therapeutics in Myeloma

Management of multiple myeloma in the newly diagnosed patient
María-Victoria Mateos,Jesús F. San Miguel
View Articletitled, Management of multiple myeloma in the newly diagnosed patient
Management of multiple myeloma in the relapsed/refractory patient
Pieter Sonneveld
View Articletitled, Management of multiple myeloma in the relapsed/refractory patient
Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies
Shaji Kumar
View Articletitled, Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies

Practical Aspects of Acute and Chronic Pain Management in Sickle Cell Disease

Optimizing the care model for an uncomplicated acute pain episode in sickle cell disease
Paul Telfer,Banu Kaya
View Articletitled, Optimizing the care model for an uncomplicated acute pain episode in sickle cell disease
Pain-measurement tools in sickle cell disease: where are we now?
Deepika S. Darbari,Amanda M. Brandow
View Articletitled, Pain-measurement tools in sickle cell disease: where are we now?
Targeting novel mechanisms of pain in sickle cell disease
Huy Tran,Mihir Gupta,Kalpna Gupta
View Articletitled, Targeting novel mechanisms of pain in sickle cell disease
Evidence-Based Minireview
Responsiveness of Patient-Reported Outcome Measurement Information System (PROMIS) pain domains and disease-specific patient-reported outcome measures in children and adults with sickle cell disease
Susanna Curtis,Amanda M. Brandow
View Articletitled, Responsiveness of Patient-Reported Outcome Measurement Information System (PROMIS) pain domains and disease-specific patient-reported outcome measures in children and adults with sickle cell disease

The Challenge of Primary and Secondary Central Nervous System Lymphoma

Biology of CNS lymphoma and the potential of novel agents
James L. Rubenstein
View Articletitled, Biology of CNS lymphoma and the potential of novel agents
Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents
Andrés José María Ferreri
View Articletitled, Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents
Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies
Kerry J. Savage
View Articletitled, Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies

The Changing Landscape of Hemophilia Therapy

Hemophilia gene therapy comes of age
Lindsey A. George
View Articletitled, Hemophilia gene therapy comes of age
Using pharmacokinetics to individualize hemophilia therapy
Alfonso Iorio
View Articletitled, Using pharmacokinetics to individualize hemophilia therapy
Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy
Margaret V. Ragni
View Articletitled, Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy

The Expanding Role of Immunotherapy in Non-Hodgkin Lymphoma

Role of the microenvironment across histological subtypes of NHL
Karin Tarte
View Articletitled, Role of the microenvironment across histological subtypes of NHL
Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond
Stephen M. Ansell
View Articletitled, Harnessing the power of the immune system in non-Hodgkin lymphoma: immunomodulators, checkpoint inhibitors, and beyond
Developing T-cell therapies for lymphoma without receptor engineering
Melanie Grant,Catherine M. Bollard
View Articletitled, Developing T-cell therapies for lymphoma without receptor engineering

Therapeutic Apheresis as an Immunomodulatory Tool

Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP)
Jeffrey L. Winters
View Articletitled, Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP)
Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease
Jennifer Schneiderman
View Articletitled, Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease
HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities
Douglas E. Gladstone,Maria P. Bettinotti
View Articletitled, HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities

Thrombocytopenia in Hospitalized Patients

Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy
Marie Scully
View Articletitled, Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy
Assessing thrombocytopenia in the intensive care unit: the past, present, and future
Ryan Zarychanski,Donald S. Houston
View Articletitled, Assessing thrombocytopenia in the intensive care unit: the past, present, and future
HITs and misses in 100 years of heparin
Lawrence Rice
View Articletitled, HITs and misses in 100 years of heparin

Thrombosis, Devices, and Interventions

Anticoagulation with VADs and ECMO: walking the tightrope
Leslie Raffini
View Articletitled, Anticoagulation with VADs and ECMO: walking the tightrope
Thrombectomy and thrombolysis for the prevention and treatment of postthrombotic syndrome
Suresh Vedantham
View Articletitled, Thrombectomy and thrombolysis for the prevention and treatment of postthrombotic syndrome
Inferior vena cava filter use and patient safety: legacy or science?
William Geerts,Rita Selby
View Articletitled, Inferior vena cava filter use and patient safety: legacy or science?

When Graft Versus Tumor Fails: The Biology and Treatment of Relapse after Allogeneic Stem Cell Transplantation

Graft versus tumor effects and why people relapse
J. H. Frederik Falkenburg,Inge Jedema
View Articletitled, Graft versus tumor effects and why people relapse
Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation
Robert J. Soiffer,Yi-Bin Chen
View Articletitled, Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation
Cells to prevent/treat relapse following allogeneic stem cell transplantation
Andrew C. Dietz,Alan S. Wayne
View Articletitled, Cells to prevent/treat relapse following allogeneic stem cell transplantation
All Issues
Targeted medical therapies for vascular anomalies
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma
Transplant in ALL: who, when, and how?
Ph− ALL: immunotherapy in upfront treatment
Ph+ ALL: new approaches for upfront therapy
  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal